Climb Bio (CLYM) EPS (Basic) (2020 - 2026)
Climb Bio filings provide 7 years of EPS (Basic) readings, the most recent being -$0.2 for Q1 2026.
- Quarterly EPS (Basic) rose 35.48% to -$0.2 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$0.77 through Mar 2026, up 65.16% year-over-year, with the annual reading at -$0.88 for FY2025, 42.48% up from the prior year.
- EPS (Basic) hit -$0.2 in Q1 2026 for Climb Bio, up from -$0.25 in the prior quarter.
- Across five years, EPS (Basic) topped out at $0.04 in Q4 2024 and bottomed at -$1.81 in Q2 2024.
- Average EPS (Basic) over 5 years is -$0.35, with a median of -$0.2 recorded in 2026.
- Peak annual rise in EPS (Basic) hit 130.77% in 2024, while the deepest fall reached 852.63% in 2024.
- Climb Bio's EPS (Basic) stood at -$0.29 in 2022, then soared by 55.17% to -$0.13 in 2023, then surged by 130.77% to $0.04 in 2024, then plummeted by 725.0% to -$0.25 in 2025, then rose by 20.0% to -$0.2 in 2026.
- Per Business Quant, the three most recent readings for CLYM's EPS (Basic) are -$0.2 (Q1 2026), -$0.25 (Q4 2025), and -$0.19 (Q3 2025).